HomeIndustriesHealthcareTarsus Pharmaceuticals (TARS) CEO On First & Only Demodex Blepharitis Treatment

Tarsus Pharmaceuticals (TARS) CEO On First & Only Demodex Blepharitis Treatment

Tarsus Pharmaceuticals (TARS) has the first and only approved treatment for Demodex Blepharitis, Xdemvy. The FDA approved Xdemvy for treatment of Demodex Blepharitis in July 2023. CEO of Tarsus Pharmaceuticals Bobby Azamian, MD, PhD joins Oliver Renick to discuss the biopharmaceutical company. The company focuses on novel therapies or ophthalmic conditions. Tune in to find out more about the stock market today.

Morning Trade Live

09 Jan 2024

SHARE

ON AIR
8:00 pm
Next Gen Investing
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
education
5:00 am
Liz Ann Live
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Market Overtime
REPLAY
8:00 am
Market Overtime
REPLAY
8:30 am
Market On Close
REPLAY
education
10:00 am
Schwab 2026 Outlook
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Liz Ann Live
REPLAY
1:30 pm
The Wrap
REPLAY
3:00 pm
Market Overtime
REPLAY
4:00 pm
Market Overtime
REPLAY
4:30 pm
Market On Close
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Fast Market
REPLAY
ON AIR
8:00 pm
Next Gen Investing
REPLAY
education
9:00 pm
Liz Ann Live
REPLAY
9:30 pm
The Wrap
REPLAY
11:00 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor